MedTrace Logo

Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

NCT01373515 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2022-10-10

No results posted yet for this study

Summary

This is an open label phase 1 feasibility and safety dose escalation study. The main objective is to evaluate the safety of DCP-001 intradermal vaccination in patients with AML.

Conditions

  • Acute Myeloid Leukemia (AML)
  • Leukemic Dendritic Cell Vaccination

Interventions

BIOLOGICAL

DCP-001

4 bi-weekly vaccinations

Sponsors & Collaborators

  • Mendus

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2013-02-28
Completion
2013-05-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01373515 on ClinicalTrials.gov